Prazosin Hydrochloride Capsule
Category: Cardiovascular
FDA status: To Be Discontinued · Last FDA update: Apr 28, 2023 · First posted: Apr 28, 2023 · 1 manufacturers, 3 listed presentations
As of Apr 28, 2023, the FDA lists Prazosin Hydrochloride Capsule as being discontinued. Of 3 manufacturer presentations, 3 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Minipress, Capsule, 1 mg (NDC 0069-4310-71) NDC 0069-4310-71 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023 |
| Minipress, Capsule, 2 mg (NDC 0069-4370-71) NDC 0069-4370-71 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023 |
| Minipress, Capsule, 5 mg (NDC 0069-4380-71) NDC 0069-4380-71 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023 |
Related medications in shortage
Other Cardiovascular medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Prazosin Hydrochloride Capsule (FDA data as of Apr 28, 2023). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Prazosin Hydrochloride Capsule. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/prazosin-hydrochloride-capsule.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).